Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

Physiology of Hyperuricemia and Urate-Lowering Treatments

Caroline BennPfizer Ltd., Cambridge, United KingdomPinky DuaPfizer Ltd., Cambridge, United KingdomRachel GurrellPfizer Ltd., Cambridge, United KingdomPeter T. LoudonPfizer Ltd., Cambridge, United KingdomAndrew PikeDMPK, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United KingdomRichard StorerIMED Biotech Unit, Medicinal Chemistry, Discovery Sciences, AstraZeneca, Cambridge, United KingdomCiara VangjeliPfizer Ltd., Cambridge, United Kingdom
2018en
ABI

Аннотация

Gout is the most common form of inflammatory arthritis and is a multifactorial disease typically characterized by hyperuricemia and monosodium urate crystal deposition predominantly in, but not limited to, the joints and the urinary tract. The prevalence of gout and hyperuricemia has increased in developed countries over the past two decades and research into the area has become progressively more active. We review the current field of knowledge with emphasis on active areas of hyperuricemia research including the underlying physiology, genetics and epidemiology, with a focus on studies which suggest association of hyperuricemia with common comorbidities including cardiovascular disease, renal insufficiency, metabolic syndrome and diabetes. Finally, we discuss current therapies and emerging drug discovery efforts aimed at delivering an optimized clinical treatment strategy.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 3Использованных источников: 0